Citi Pharma Limited (PSX:CPHL)
Pakistan · Delayed Price · Currency is PKR 80.64
-0.81 (-0.99%)
At close: May 8, 2026
Citi Pharma Income Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 13,841 | 13,154 | 12,409 | 12,397 | 9,780 | 5,795 | |
Revenue Growth (YoY) | 6.68% | 6.00% | 0.10% | 26.76% | 68.75% | 64.29% |
Cost of Revenue | 11,280 | 11,136 | 10,823 | 10,890 | 8,417 | 5,024 |
Gross Profit | 2,560 | 2,018 | 1,586 | 1,507 | 1,363 | 771.9 |
Selling, General & Admin | 476.15 | 413.36 | 380.55 | 339.64 | 369.6 | 200.93 |
Operating Expenses | 476.15 | 413.36 | 380.55 | 339.64 | 369.6 | 200.93 |
Operating Income | 2,084 | 1,604 | 1,206 | 1,167 | 993.48 | 570.97 |
Interest Expense | -368.18 | -317.65 | -295.43 | -133.84 | -57.76 | -35.74 |
Interest & Investment Income | 1.92 | 1.92 | 23.77 | 13.54 | 20.95 | - |
Currency Exchange Gain (Loss) | -6.05 | -6.05 | 65.52 | -245.68 | -6.85 | -0.64 |
Other Non Operating Income (Expenses) | -36.45 | 69.34 | 256.3 | 175.03 | 110.75 | -34.84 |
EBT Excluding Unusual Items | 1,676 | 1,352 | 1,256 | 976.52 | 1,061 | 499.75 |
Gain (Loss) on Sale of Investments | 2.7 | 2.7 | 25.4 | -37.42 | - | - |
Other Unusual Items | - | - | - | 18.16 | - | - |
Pretax Income | 1,678 | 1,355 | 1,281 | 957.25 | 1,061 | 499.75 |
Income Tax Expense | 581.6 | 462.47 | 447.74 | 299.27 | 406.88 | 147.98 |
Net Income | 1,097 | 892.04 | 833.46 | 657.98 | 653.69 | 351.77 |
Net Income to Common | 1,097 | 892.04 | 833.46 | 657.98 | 653.69 | 351.77 |
Net Income Growth | 31.98% | 7.03% | 26.67% | 0.66% | 85.83% | 145.28% |
Shares Outstanding (Basic) | 228 | 228 | 228 | 228 | 227 | 106 |
Shares Outstanding (Diluted) | 228 | 228 | 228 | 228 | 227 | 186 |
Shares Change (YoY) | -0.07% | - | - | 0.70% | 21.65% | 88.38% |
EPS (Basic) | 4.80 | 3.90 | 3.65 | 2.88 | 2.88 | 3.31 |
EPS (Diluted) | 4.80 | 3.90 | 3.65 | 2.88 | 2.88 | 1.88 |
EPS Growth | 31.94% | 6.90% | 26.67% | - | 53.04% | 29.90% |
Free Cash Flow | -741.71 | -470.77 | 769.4 | -1,283 | -923.43 | -52.3 |
Free Cash Flow Per Share | -3.25 | -2.06 | 3.37 | -5.62 | -4.07 | -0.28 |
Dividend Per Share | 3.500 | 3.500 | 3.250 | 2.500 | - | 1.364 |
Dividend Growth | 7.69% | 7.69% | 30.00% | - | - | - |
Gross Margin | 18.50% | 15.34% | 12.78% | 12.16% | 13.94% | 13.32% |
Operating Margin | 15.06% | 12.20% | 9.72% | 9.42% | 10.16% | 9.85% |
Profit Margin | 7.92% | 6.78% | 6.72% | 5.31% | 6.68% | 6.07% |
Free Cash Flow Margin | -5.36% | -3.58% | 6.20% | -10.35% | -9.44% | -0.90% |
EBITDA | 2,265 | 1,767 | 1,341 | 1,258 | 1,066 | 631.68 |
EBITDA Margin | 16.37% | 13.43% | 10.81% | 10.15% | 10.90% | 10.90% |
D&A For EBITDA | 181.06 | 162.75 | 135.67 | 90.59 | 72.84 | 60.71 |
EBIT | 2,084 | 1,604 | 1,206 | 1,167 | 993.48 | 570.97 |
EBIT Margin | 15.06% | 12.20% | 9.72% | 9.42% | 10.16% | 9.85% |
Effective Tax Rate | 34.66% | 34.14% | 34.95% | 31.26% | 38.36% | 29.61% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.